Nabriva Therapeutics plc Annual Cost of Revenue in USD from 2019 to 2022

Taxonomy & unit
us-gaap: USD
Description
The aggregate cost of goods produced and sold and services rendered during the reporting period.
Summary
Nabriva Therapeutics plc quarterly/annual Cost of Revenue history and growth rate from 2019 to 2022.
  • Nabriva Therapeutics plc Cost of Revenue for the quarter ending June 30, 2023 was $9.07M, a 104% increase year-over-year.
  • Nabriva Therapeutics plc Cost of Revenue for the twelve months ending June 30, 2023 was $34.3M, a 98.4% increase year-over-year.
  • Nabriva Therapeutics plc annual Cost of Revenue for 2022 was $28.6M, a 117% increase from 2021.
  • Nabriva Therapeutics plc annual Cost of Revenue for 2021 was $13.1M, a 1616% increase from 2020.
  • Nabriva Therapeutics plc annual Cost of Revenue for 2020 was $766K, a 994% increase from 2019.
Cost of Revenue, Trailing 12 Months (USD)
Cost of Revenue, Annual (USD)
Cost of Revenue, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2022 $28.6M +$15.4M +117% Jan 1, 2022 Dec 31, 2022 10-K 2023-04-17
2021 $13.1M +$12.4M +1616% Jan 1, 2021 Dec 31, 2021 10-K 2023-04-17
2020 $766K +$696K +994% Jan 1, 2020 Dec 31, 2020 10-K 2023-04-17
2019 $70K Jan 1, 2019 Dec 31, 2019 10-K 2022-03-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.